chr19-35851340-C-T
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM1PM2PP3PP5
The ENST00000378910.10(NPHS1):c.319G>A(p.Ala107Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000031 in 1,613,644 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A107E) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000378910.10 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NPHS1 | NM_004646.4 | c.319G>A | p.Ala107Thr | missense_variant | 3/29 | ENST00000378910.10 | NP_004637.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NPHS1 | ENST00000378910.10 | c.319G>A | p.Ala107Thr | missense_variant | 3/29 | 1 | NM_004646.4 | ENSP00000368190 | P2 | |
NPHS1 | ENST00000353632.6 | c.319G>A | p.Ala107Thr | missense_variant | 3/28 | 5 | ENSP00000343634 | A2 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152180Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000161 AC: 4AN: 249074Hom.: 0 AF XY: 0.00000741 AC XY: 1AN XY: 134936
GnomAD4 exome AF: 0.0000322 AC: 47AN: 1461464Hom.: 0 Cov.: 35 AF XY: 0.0000316 AC XY: 23AN XY: 727028
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152180Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74332
ClinVar
Submissions by phenotype
Finnish congenital nephrotic syndrome Pathogenic:3Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Nov 03, 2018 | The NPHS1 c.319G>A (p.Ala107Thr) variant has been reported in a compound heterozygous state with a splice site variant in one individual with congenital Finnish nephrosis (Philippe et al. 2008). The p.Ala107Thr variant was absent from 188 control chromosomes, but is reported at a frequency of 0.000027 in the European (non-Finnish) population from the Genome Aggregation Database. Functional studies in HeLa cells demonstrated that the p.Ala107Thr variant protein localized to the plasma membrane with wild type nephrin. In HEK293 cells, co-immunoprecipitation studies showed that both nephrin homodimerization and NEPH1 heterodimerization were intact and unaffected by the p.Ala107Thr variant (Philippe et al. 2008). Based on the limited evidence, the p.Ala107Thr variant is classified as a variant of unknown significance but suspicious for pathogenicity for congenital nephrotic syndrome. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Likely pathogenic, no assertion criteria provided | literature only | Juha Muilu Group; Institute for Molecular Medicine Finland (FIMM) | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genomics England Pilot Project, Genomics England | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 23, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 03, 2021 | NM_004646.3(NPHS1):c.319G>A(A107T) is a missense variant classified as a variant of uncertain significance in the context of nephrotic syndrome, NPHS1-related. A107T has been observed in cases with relevant disease (PMID: 18614772, 20507940, 25349199). Functional assessments of this variant are available in the literature (PMID: 18614772). A107T has been observed in population frequency databases (gnomAD: OTH 0.02%). In summary, there is insufficient evidence to classify NM_004646.3(NPHS1):c.319G>A(A107T) as pathogenic or benign. Please note: this variant was assessed in the context of healthy population screening. - |
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Genomic Research Center, Shahid Beheshti University of Medical Sciences | May 03, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 27, 2023 | This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 107 of the NPHS1 protein (p.Ala107Thr). This variant is present in population databases (rs386833933, gnomAD 0.003%). This missense change has been observed in individual(s) with steroid-resistant nephrotic syndrome (PMID: 18614772, 25349199). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 56494). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on NPHS1 protein function. Experimental studies have shown that this missense change does not substantially affect NPHS1 function (PMID: 18614772). This variant disrupts the p.Ala107 amino acid residue in NPHS1. Other variant(s) that disrupt this residue have been observed in individuals with NPHS1-related conditions (PMID: 20172850, 20798252), which suggests that this may be a clinically significant amino acid residue. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 15, 2023 | Variant summary: NPHS1 c.319G>A (p.Ala107Thr) results in a non-conservative amino acid change located in the Immunoglobulin subtype 2 (IPR003598) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 249074 control chromosomes (gnomAD). c.319G>A has been reported in the literature in individuals affected with Nephrotic Syndrome, Type 1, (Philippe_2008, Sadowski_2015), and one was reported as compound heterozygous with a (likely) pathogenic variant. These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 18614772, 25349199). Three submitters have cited clinical-significance assessments for this variant to ClinVar after 2014, and classified it as uncertain significance (n=2) or likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at